Background: The aim of this study was to determine the chemosensitivity of pregnancy-associated breast cancer (PABC) in the neoadjuvant setting by comparing the observed pathological complete response (pCR) rate with the rate predicted by a validated nomogram.
introduction Pregnancy-associated breast cancer (PABC) is defined as breast cancer diagnosed during pregnancy or within 1 year of delivery. It accounts for 8% of breast cancer cases occurring in women younger than 45 years of age [1] . PABC has been reported to have specific phenotypes such as low hormone receptor positivity and a high rate of HER2 overexpression [2, 3] . This breast cancer is described as being particularly aggressive and having a worse prognosis than non-PABC [4] . PABC may actually be several different diseases, such as breast cancers that are closely related to pregnancy in their oncogenesis as well as breast cancers that are completely independent of pregnancy. An improvement in the understanding of PABC may help to differentiate these entities and distinguish their chemosensitivities. However, the chemosensitivity of PABC is not well known and there is frequently a delay in diagnosis. The tumor size of these breast cancers has been reported to be greater than that of non-PABCs [5, 6] . Neoadjuvant chemotherapy (NACT) is therefore an option for PABC, and anthracycline-based regimens have been considered safe during pregnancy [7] [8] [9] . Complete pathological eradication of the invasive cancer, the pathological complete response (pCR), reveals chemosensitivity because it provides a powerful early surrogate for long-term survival and is considered an indicator of benefit from chemotherapy [10] . We previously developed a clinical pathological variable-based on the NACT response prediction model [11] . This model was built using data from patients who received preoperative NACT so that tumor response to treatment could be measured directly. Our response prediction nomogram was subsequently validated on two sets of independent cases from two different institutions original article mathematical and statistical analysis. To evaluate the theoretical response rate to chemotherapy, we used well-calibrated logistic regression-based nomograms that we previously developed and published [12, 15] . We built these models in training cohorts and validated them in independent cohorts from centers other than the training cohort. We tested clinicopathological characteristics (age, tumor size, nodal status, histologic type and grade, estrogen receptor status, multifocality, and number of courses of preoperative chemotherapy) in a multivariate analysis for association with pCR. We then developed interfaces to calculate the individual probability of pCR according to the chemotherapy regimen given. Therefore, the use of nomograms provided a multivariate estimation of pCR. By integrating the interactions of multiple parameters, nomograms maximized the accuracy of the predictions. To evaluate the chemosensitivity of PABC, we compared individual probabilities of pCR in patients with PABC using the nomograms and the pCR rates observed. We used two parameters to determine whether PABC was as chemosensitive as non-PABC: discrimination and calibration [16] . Discrimination (i.e. whether the relative rankings of individual predictions were in the correct order) was quantified with the area under the receiveroperating characteristic curve (AUC). The AUC is identical to the concordance index and ranged from 0 to 1 (1 indicating perfect concordance, 0.5 indicating no association, and 0 indicating perfect discordance). Confidence intervals were calculated using a bias-corrected bootstrap with 1000 iterations. Calibration corresponds to the agreement between the observed outcome frequencies and the predicted probabilities. The results are displayed in a calibration graph that shows the relationship between the observed outcome frequencies and the predicted probabilities for two groups of patients categorized according to a median split (semi-cohorts with the lowest/highest predicted pCR rate). A calibration curve can be approximated by a regression line with the intercept a and slope b. These parameters can be estimated in a linear regression model with the event as the outcome and the linear predictor as the only covariate. Well-calibrated models have a = 0 and b = 1 [ideal line: intercept at (0,0), slope: 45°]. Therefore, a sensible measure of calibration (the unreliability index) is a likelihood ratio statistic testing the null hypothesis that a = 0 and b = 1. The statistic has a v 2 distribution with 2 df. To calculate the power of this test (necessary to estimate sample size effect), we 
results
The study included 57 patients who received four courses of anthracycline-based chemotherapy or four courses of anthracycline-based chemotherapy followed by four courses of paclitaxel, but since data were missing for nine patients, only 48 patients were included in the analysis. Among them, 10 had pCR (no residual disease in the breast and nodes). Twenty-two patients (46%) had metastatic nodes at surgery. We calculated the individual probability of pCR in response to neoadjuvant treatment with specific nomograms corresponding to the chemotherapy regimen administered.
Overall, as reported in Table 2 , the observed rates of pCR were concordant with predictions in the whole sample and in the subgroups that were analyzed: (i) discriminations assessed by AUC were significantly above 0.5, except for patients who were not treated with neoadjuvant taxanes, and (ii) calibration curves were satisfactory. Unreliability indexes were not significant.
prediction of probability of pCR to NACT in the whole sample
For the whole sample, the observed rates were in accordance with predictions, as demonstrated by discrimination and calibration.
Discrimination. In the original training set, the AUC obtained with the logistic regression model was 0.77 (95% CI 0.74-0.80). This means that given two randomly selected patients, the patient with the worse outcome was predicted to have a worse outcome in 77% of possible pairs with discordant outcome. In this study population, including only PABC, the AUC for the logistic regression model was significant at 0.77 (95% CI 0.66-0.87). The receiver-operating characteristic (ROC) curve is reported in Figure 1 .
Calibration. The calibration of the nomograms to predict pCR in PABC is reported in Figure 2 . In this figure, patients were separated into two subgroups according to their predicted probability of pCR (x-axis). The observed pCR rate at histopathologic examination is reported on the y-axis. Perfect predictions are plotted on the ideal line: intercept at (0,0), slope: 45°. The predicted probability and observed proportion of pCR of patients with the lowest predicted pCR were 7% and 8%, respectively. The predicted probability and observed proportion of pCR of patients with the highest predicted pCR were 35% and 33%, respectively. The differences between predictions and observations were not significant (P = 0.76, power = 0.91).
Thus, using a nomogram developed to predict pCR for women with non-PABC provided accurate predictions for women with PABC. We deduce from this finding that PABCs are as chemosensitive as non-PABCs.
progression under NACT
One of the main risks of NACT is progression during treatment, so we specifically recorded the occurrence of this phenomenon. Three patients clinically progressed under chemotherapy and two of them required a strategic change. This number is in accordance with previous reports. prediction of probability of pCR to NACT in PABC according to the onset of chemotherapy
We evaluated whether there were differences in discrimination and calibration if the onset of NACT was during pregnancy versus after delivery (Table 2) .
Discrimination. For patients who began chemotherapy during pregnancy, the AUC of predictions using nomograms was 0.94 (95% CI 0.88-1.00). With patients treated only after delivery, Table 2 . Predicted probability of pCR according to the nomogram and the percentage observed for the whole sample and for subgroups Calibration. The calibration of the nomograms to predict pCR in PABC according to the onset of chemotherapy is reported in Figure 3 . There was no significant difference between predicted probabilities and observed proportions, regardless of the onset of chemotherapy (Ps = 0.29 and 0.51 for chemotherapy started during pregnancy and after delivery, respectively; power 0.32 and 0.8, respectively).
prediction of probability of pCR to NACT in PABC according to the use of taxanes
We evaluated whether there were differences in pCR rates according to the regimen administered (taxane or no taxanes) ( Table 2) .
Discrimination. For patients who received only anthracyclines without taxanes, the AUC was 0.59 (95% CI 0.37-0.81). Therefore, the discrimination in this sample was insufficient. For patients treated with neoadjuvant anthracyclines and taxanes, the AUC was 0.84 (95% CI 0.74-0.93).
Calibration. The calibration of the nomograms to predict pCR in PABC according to the chemotherapy regimen administered is reported in Figure 4 . The calibration of the prediction was average for patients treated only with neoadjuvant anthracyclines. The observed pCR rate was less than the expected pCR rate according to individual predictions based on patient characteristics. The calibration curve was poorly calibrated. The P value of the unreliability index did not reach significance (0.15), but there was a lack of power due to the sample size (power = 0.70). This means that some cases of PABC are less likely to be chemosensitive to anthracycline-only NACT compared with non-PABC cases. Combined with the poor discrimination, this suggests that anthracycline-only NACT is not optimal for the treatment of PABC. The calibration of the logistic regression model was excellent for patients treated with neoadjuvant anthracycline plus taxanes (P = 0.7). For patients with the highest predicted pCR to anthracycline plus taxane-based NACT, the rate of pCR 
discussion
According to international recommendations, the treatment of PABC should adhere closely to standardized protocols for patients without concomitant pregnancy [17] . However, PABC may have specific characteristics, as its pathogenic pathway is probably different from that of non-PABC [18, 19] . Tumorigenesis in the breast is significantly influenced by hormonal factors, but the precise mechanisms of tumor induction and promotion are still poorly understood. Chemosensitivity is a cornerstone of global treatment success.
In this study, we show that PABCs are as chemosensitive as non-PABCs. This was shown through the use of nomograms. Therefore, this study also provides a proof of principle that nomograms can be used to perform clinical studies. If chemotherapy can be administered during pregnancy, the choice of the neoadjuvant setting remains a strategic one with the risk (even if low) of disease progression. The particular characteristics of PABC and pharmacokinetic changes that occur in pregnancy, such as alterations in plasma volume distribution, may impact chemosensitivity [20] . Preoperative chemotherapy, initially used only for locally advanced breast cancer, has become more common for patients with operable disease [21] . Achieving pCR is a strong independent predictor of disease-free state and overall survival for patients with breast cancer, and it is considered a surrogate marker of chemosensitivity [22, 23] . We investigated the chemosensitivity of PABC because there is a lack of evidence in the literature suggesting that the behavior of these particular cancers is similar to non-PABC. To our knowledge, this question has never been addressed. The most important studies have reported the safety of anthracycline-based chemotherapy, but few patients had actually received NACT [7, 9, 24] . In the largest series reported by Hahn et al. [25] , 25 patients received NACT and had a pCR rate of 32%. Our results confirm this study and support a neoadjuvant strategy for treating PABC. Our results suggest that PABC patients should receive taxanes as part of their regimen because the chemosensitivity to a regimen based only on anthracyclines is insufficient, while adding taxanes results in a better chemosensitivity compared with non-PABC cases. A recent review of the literature showed a favorable toxicity profile of taxanes during the second and third trimesters of pregnancy, and these results are supported by pharmacological evidence [26] .
Comparing the effects of NACT versus adjuvant chemotherapy in PABC is difficult because of the low prevalence of NACT, although it is becoming more frequent as the age of first pregnancy in some countries increases. Nomograms may be a useful way to test a new treatment or therapeutic strategy without randomization in the case of a rare situation. They can provide theoretical individualized outcomes based on validated multivariate analyses [11] . Any difference between the predicted probability and the observed proportion reflects that the new treatment allocation or strategy modifies the outcome. Of course, such a multivariable analysis can never adjust for unmeasured or unknown confounders. Nevertheless, our study provides a proof of principle that may improve knowledge of PABC behavior. The observed pCR for PABC treated with an NACT based on anthracyclines was good at 17% (Table 2 ) and may be interpreted as satisfactory. However, based on patient and tumor characteristics, the pCR rate was expected to be 29%. Only nomograms allow corrections for individual predictions. Compared with other nonrandomized study designs, the use of nomograms has several advantages. First, the probability of pCR is based on numerous criteria and includes the respective weights of these criteria and potential interactions. Second, the robustness of our predictor has been validated in a large group of patients and provides a multivariate stratification for maximizing the accuracy of estimation that might be superior to simple matching, especially if it is based on more extensive information (larger datasets). Third, it could integrate the chemotherapy regimen used because we developed several nomograms. Moreover, these nomograms use previous information when a new drug is added to a regimen. There are, however, limitations to our study that must be acknowledged. First, the number of cases was limited (n = 48). Nevertheless, the power of the calibration assessment was 0.91 for the test based on the whole cohort and ranged between 0.32 (n = 11) and 0.8 (n = 37). The interpretation of our study is limited by a lack of power. Second, the number of criteria that are included in the nomograms is limited; for example, HER2 status was not taken into account. Additional studies and nomograms including those that consider HER2 status should be conducted. PABC may indeed include different diseases, such as breast cancers that are closely related to pregnancy in their oncogenesis as well as breast cancers that are completely independent of pregnancy. An improvement in the understanding of PABC in the near future may help to differentiate these entities 
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